Recent News

By Category: Biosafety

FAZD Center’s Enhanced Passive Surveillance System

November 1, 2013
| Filed under Agriculture and Biosafety
Share

Request for Proposal – Joint Biological Tactical Detection System

(GlobalBiodefense) The U.S. Army Contracting Center, on behalf of the Joint Project Manager – Nuclear Biological Chemical Contamination Avoidance (JPM-NBCCA), has issued a pre-solicitation notice for the Joint Biological Tactical Detection System (JBTDS) Engineering & Manufacturing Development phase. The effort includes options for Low Rate Initial Production and Full Rate Production.

October 31, 2013
| Filed under North America, Biosafety, and Research
Share

Higher-Level TB Research to Begin at NEIDL

(BostonUniversity) BU’s National Emerging Infectious Diseases Laboratories will begin doing tuberculosis research at a higher biosafety level in the coming months, following approval of the work by the Boston Public Health Commission. The research will be transferred from another lab on the Medical Campus. TB researchers Igor Kramnik, a School of Medicine professor of medicine Read More »

October 31, 2013
| Filed under North America, Biosafety, and Research
Share

Policing the New Scientific Frontier of Synthetic Biology

(ForeignAffairs) Ongoing research and discoveries in the life sciences — the latest and most promising involving synthetic biology — have led to extraordinary advances that will benefit society. But criminals and terrorists could manipulate such advances to disrupt public safety and national security. Since its founding in 1923, Interpol has learned that the most effective Read More »

October 28, 2013
| Filed under Africa, Asia/Pacific, Europe, Middle East, North America, South America, South Asia, Biosafety, Bioterrorism, International, Policy & Initiatives, and Research
Share

Deadly gaps persist in new drug development for neglected diseases

(EurekaAlert) In a study published today in the open-access journal The Lancet Global Health, the Drugs for Neglected Diseases initiative (DNDi) and other researchers report a persistent deficiency in truly new therapeutics for neglected diseases, despite nominal progress and an acceleration in research and development (R&D) efforts. This continued ‘fatal imbalance’ in medical R&D points Read More »